Antibe Therapeutics Faces Receivership and Delisting
Company Announcements

Antibe Therapeutics Faces Receivership and Delisting

Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.

Antibe Therapeutics Inc. has undergone significant changes, with the appointment of FTI Consulting Canada Inc. as receiver following the termination of its CCAA proceedings, and the resignation of five board members. Additionally, the company’s common shares are set to be delisted from the TSX on May 24, 2024.

For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.

Related Articles
Ryan AdistATBPF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TipRanks Canadian Auto-Generated NewsdeskAntibe Therapeutics Seeks Crucial Stay Extension
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App